Owl Peak Labs, a life sciences company that develops new screening solutions to detect colorectal cancer, announced today the fully subscribed closure of its seed round of $1.5 million. The funding will be used to further develop innovative diagnostic solutions using Owl Peak Labs’ novel imaging technology to detect anomalies of the gastrointestinal tract at the earliest stage. Owl Peak Labs will also continue to invest in its Artificial Intelligence platform to aid in early detection.
“The entire Owl Peak Labs team is excited to close our seed funding round with a strong institutional partner to forward our mission of efficacious and equitable screening for all,” said Tim Harvey, Co-CEO of Owl Peak Labs.
“This is an important step towards our goal of developing better at-home colorectal cancer screening modalities,” Co-CEO Dr. Taison Bell, M.D. added. “We are incredibly excited.”
Colorectal cancer is known as the least prevented, though most preventable, cancer, accounting for 10% of cancer cases but second overall in cancer deaths. Only 64% of Americans undergo recommended routine screening, well below the CDC’s 80% goal, contributing to over 53,000 deaths in the United States each year. But if it is caught early, colorectal cancer can be treated successfully. That is why Co-CEOs Tim Harvey and Taison Bell decided to develop better colorectal cancer screening solutions when they founded Owl Peak Labs in 2019 while students at the University of Virginia Darden School of Business.
About Owl Peak Labs
Owl Peak Labs is a life sciences company that innovates hardware and software solutions that detect early-stage cancer more accurately and faster than current products on the market. For more information, visit www.owlpeaklabs.com.